Earnings Summary

Acorda Therapeutics, Inc.’s revenue jumped 70.66% since last year same period to $37.99Mn in the Q1 2024. On a quarterly growth basis, Acorda Therapeutics, Inc. has generated 0% jump in its revenue since last 3-months.

Acorda Therapeutics, Inc.’s net profit fell -1194.35% since last year same period to $-217.76Mn in the Q1 2024. On a quarterly growth basis, Acorda Therapeutics, Inc. has generated 0% jump in its net profits since last 3-months.

Acorda Therapeutics, Inc.’s net profit margin fell -658.45% since last year same period to -573.28% in the Q1 2024. On a quarterly growth basis, Acorda Therapeutics, Inc. has generated 0% jump in its net profit margins since last 3-months.

Acorda Therapeutics, Inc.’s price-to-earnings ratio after this Q1 2024 earnings stands at 0.34.

Acorda Therapeutics, Inc.’s earning per share (EPS) estimates for the current quarter stand at -31.2 - a -20700% fall from last quarter’s estimates.

Acorda Therapeutics, Inc.’s earning per share (EPS) estimates for the current year stand at -31.2.

Acorda Therapeutics, Inc.’s earning per share (EPS) fell -689.53% since last year same period to -225.81 in the Q1 2024. This indicates that the Acorda Therapeutics, Inc. has generated -689.53% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Acorda Therapeutics, Inc.’s return on assets (ROA) stands at -0.03.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Acorda Therapeutics, Inc.’s return on equity (ROE) stands at -0.24.